Solid-Phase Synthesis of Complex Oligosaccharides
FULL PAPER
3
General Procedure for the Solid Phase Glycosylation (Procedure B):
Solid phase glycosylation was performed according to the pro-
cedure previously described.[27]
5.35 (t, J ϭ 10.3 Hz, 1 H, 2b-H), 5.43 (s, 1 H, CHPh), 5.46 (s, 1
H, CHPh), 6.9Ϫ7.41 (m, 38 H, Ar) ppm. 13C NMR (150.9 MHz,
CDCl3): δ ϭ 63.9 (C-2a), 65.8 (C-2c), 65.9 (C-5b), 66.5 (C-5d), 67.3
(C-6c), 68.4 (C-6a, C-6d), 68.3 (C-6b), 69.2 (C-2b), 70.6 (C-2d),
71.9 (C-3b), 73.0 (C-4b), 75.0 (C-5a, C-5c), 75.6 (C-4d), 76.8 (C-
4c), 77.0 (C-3d), 77.4 (C-4a), 81.1 (C-4a), 81.1 (C-3c), 82.6 (C-3a),
100.3 (C-1c), 100.7 (C-1d), 100.8 (C-1b), 102.7 (C-1a) ppm.
MALDI-MS: m/z ϭ 1669.7 [M ϩ Naϩ]. C90H92N4O26 (1645.7).
General Procedure for Cleavage (Procedure C): Cleavage was per-
formed according to the procedure previously described.[27]
Resin 21: The Fmoc group of 4b was removed using procedure A.
Resin 22: Resin 21 was glycosylated with donor 7 according to pro-
cedure B using 0.3 equiv. of TMSOTf at Ϫ40 °C.
Resin 25: Resin 21 was glycosylated with donor 8 according to pro-
cedure B using 0.3 equiv. of TMSOTf at Ϫ20 °C.
4-(Acetoxymethyl)benzyl 2,3-O-Di-acetyl-4,6-O-benzylidene-β-
D-
Resin 26: The Fmoc group of 25 was removed using procedure A.
Chain elongation with donor 10 was then performed according to
procedure B using 0.3 equiv. of TMSOTf at Ϫ20 °C.
galactopyranosyl-(1Ǟ4)-2-azido-3,6-di-O-benzyl-2-deoxy-β- -gluco-
D
pyranoside (1): Resin 22 (36 µL) was treated as described in pro-
cedure C. After removal of the solvents in vacuo, the crude cleavage
residue was treated with Ac2O (1 mL) and pyridine (2 mL) for 10 h.
The resulting mixture was concentrated in vacuo and coevaporated
twice with toluene. The residue was purified by flash chromatogra-
phy (petroleum ether/ethyl acetate, 2:1) to furnish 1 (25.6 mg, 81%
overall yield) as an amorphous solid. TLC (petroleum ether/ethyl
4-(Acetoxymethyl)benzyl 2-O-Acetyl-3,4,6-tri-O-benzyl-α-
pyranosyl-(1Ǟ6)-(2,3-di-O-acetyl-4-O-benzyl-β- -galacto-
pyranosyl)(1Ǟ4)-2-azido-3,6-di-O-benzyl-2-deoxy-β- -glucopy-
D-manno-
D
D
ranoside (3): Resin 26 (24 µL) was treated as described in procedure
C. After removal of the solvents in vacuo, the crude cleavage resi-
due was treated with Ac2O (1 mL) and pyridine (2 mL) for 10 h.
The resulting mixture was concentrated in vacuo and coevaporated
twice with toluene. The residue was purified by flash chromatogra-
phy (petroleum ether/ethyl acetate, 2:1) to furnish 3 (20 mg, 63%
overall yield) as an amorphous solid. TLC (petroleum ether/ethyl
1
acetate, 2:1): Rf ϭ 0.60. [α]D ϭ Ϫ3.4 (c ϭ 1.7, CHCl3). H NMR
(600 MHz, CDCl3): δ ϭ 1.92Ϫ2.03 (m, 9 H, 3 Ac), 3.04 (s, 1 H,
3
5b-H), 3.24 (d, J ϭ 8.0 Hz, 1 H, 5a-H), 3.32 (m, 1 H, 3a-H), 3.41
(m, 1 H, 2a-H), 3.67Ϫ3.74 (m, 2 H, 6a-H, 6Јa-H), 3.82 (d, 2J ϭ
11.5 Hz, 1 H, 6b-H), 3.94 (t, 3J ϭ 9.1 Hz, 1 H, 4a-H), 4.12 (d, 2J ϭ
1
2
acetate, 1:1): Rf ϭ 0.44. [α]D ϭ ϩ1.1 (c ϭ 1.0, CHCl3). H NMR
12.1 Hz, 1 H, 6Јb-H), 4.20 (m, 1 H, 4b-H), 4.22 (d, J ϭ 8.1 Hz, 1
3
H, 1a-H), 4.41 (d, 2J ϭ 12.0 Hz, 1 H, 1/2 CH2Ph), 4.53 (d, J ϭ
(600 MHz, CDCl3): δ ϭ 1.98Ϫ2.16 (m, 12 H, 4 Ac), 3.26Ϫ3.32 (m,
3 H, 3a-H, 5c-H, 6b-H), 3.37 (m, 1 H, 5b-H), 3.44Ϫ3.49 (m, 2 H,
8.0 Hz, 1 H, 1b-H), 4.59 (d, 2J ϭ 12.1 Hz, 1 H, 1/2 CH2Ph),
4.66Ϫ4.70 (m, 4 H, 3b-H, 3/2 CH2Ph), 4.85 (d, 2J ϭ 12.1 Hz, 1 H,
1/2 CH2Ph), 5.03 (m, 4 H, 2 CH2Ph), 5.25 (m, 1 H, 2b-H), 5.38 (s,
1 H, CHPh), 7.14Ϫ740 (m, 19 H, Ar) ppm. 13C NMR (150.9 MHz,
CDCl3): δ ϭ 66.1 (C-2a), 66.58 (C-5b), 67.56 (C-6a), 68.6 (C-6b),
69.4 (C-2b), 73.36 (C-4b), 75.2 (C-5a), 75.8 (C-3b), 77.1 (C-4a),
81.2 (C-3a), 100.56 (C-1a), 100.62 (C-1b), 101.03 (CϪCHPh) ppm.
MALDI-MS: m/z ϭ 905.3 [M ϩ Naϩ]. C47H51NO14 (881.9).
3
2a-H, 6a-H), 3.53 (m, 1 H, 6Јb-H), 3.60 (d, J ϭ 9.7 Hz, 1 H, 5a-
H), 3.71Ϫ3.73 (m, 3 H, 6Јa-H, 6c-H, 6Јc-H), 3.85 (m, 2 H, 3c-H,
4b-H), 3.93Ϫ3.95 (m, 2 H, 4a-H, 4c-H), 4.23 (d, J1,2 ϭ 8.1 Hz, 1
H, 1a-H), 4.38Ϫ4.50 (m, 5 H, 5/2 CH2Ph), 4.52 (s, 1 H, 1c-H), 4.55
(d, J1,2 ϭ 8.0 Hz, 1 H, 1b-H), 4.61Ϫ4.66 (m, 4 H, 2 CH2Ph), 4.72
(d, 2J ϭ 12.0 Hz, 1 H, 1/2 CH2Ph), 4.79Ϫ4.93 (m, 5 H, 3b-H, 2
3
CH2Ph), 5.09 (s, 2 H, CH2Ph), 5.21 (s, 1 H, 2c-H), 5.30 (dd, J ϭ
3
8.3, J ϭ 10.1 Hz, 1 H, 2b-H), 7.16Ϫ7.35 (m, 34 H, Ar) ppm. 13C
Resin 23: The Fmoc group of 22 was removed using procedure A.
Chain elongation with donor 9 was then performed according to
procedure B using 0.3 equiv. of TMSOTf at Ϫ40 °C.
NMR (150.9 MHz, CDCl3): δ ϭ 64.8 (C-6b), 65.4 (C-2a), 67.5 (C-
6c), 68.1 (C-6a), 68.5 (C-2c), 70.3 (C- 2b), 71Ϫ4 (C-5a), 72.5 (C-
5b), 73.8 (C-3b, C-4a), 73.9 (C-4b), 74.9 (C-5c), 75.7 (C-4c), 77.8
(C-3c), 81.1 (C-3a), 97.9 (C-1c), 100.0 (C-1b), 100.4 (C-1a) ppm.
MALDI-MS: m/z ϭ 1381.5 [M ϩ Naϩ]. C76H83N3O20 (1358.5).
Resin 24: The Fmoc group of 23 was removed using procedure A.
Chain elongation with donor 7 was then performed according to
procedure B using 0.3 equiv. of TMSOTf at Ϫ40 °C.
Acknowledgments
4-(Acetoxymethyl)benzyl
2,3-Di-O-acetyl-4,6-O-benzylidene-β-D-
We thank the European Community (Grant No. FAIR-
CT97Ϫ3142), the Bundesministerium für Bildung und Forschung
(Grant N° 0311229), the Deutsche Forschungsgemeinschaft, and
the Fond der Chemischen Industrie for financial support of this
work. The help of A. Friemel in structural assignments is grate-
fully acknowledged.
galactopyranosyl-(1Ǟ4)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-
D
-glucopyranosyl-(1Ǟ3)-(2-O-acetyl-4,6-O-benzylidene-β-
D
D
-
-
galactopyransyl)(1Ǟ4)-2-azido-3,6-di-O-benzyl-2-deoxy-β-
glucopyranoside (2): Resin 24 (24 µL) was treated as described in
procedure C. After removal of the solvents in vacuo, the crude
cleavage residue was treated with Ac2O (1 mL) and pyridine (2 mL)
for 10 h. The resulting mixture was concentrated in vacuo and co-
evaporated twice with toluene. The residue was purified by HPLC
(ethyl acetate/hexane, 6:5) to furnish 2 (8.3 mg, 21% overall yield)
as an amorphous solid. TLC (petroleum ether/ethyl acetate, 1:1):
Rf ϭ 0.35. 1H NMR (600 MHz, CDCl3): δ ϭ 1.86Ϫ2.10 (m, 12 H,
4 Ac), 3.03 (s, 1 H, 5d-H), 3.14 (s, 1 H, 5b-H), 3.19 (d, 1 H, 5c-H),
[1]
A. Varki, Glycobiology 1993, 3, 97Ϫ130.
[2]
R. A. Dwek, Chem. Rev. 1996, 96, 683Ϫ720.
[3]
N. Sharon, H. Lis, in Glycosciences Ϫ Status and Perspectives
(Eds.: H.-J. Gabius, S. Gabius), Chapman and Hall; Weinheim,
3
3
1997, 113Ϫ162.
3.24 (t, J ϭ 9.3 Hz, 1 H, 3c-H), 3.40 (t, J ϭ 9.7 Hz, 1 H, 2c-H),
[4]
R. R. Schmidt, Angew. Chem. 1986, 98, 213Ϫ236; Angew.
3.54 (dd, 3J ϭ 3.4 Hz, 1 H, 3d-H), 3.60 (m, 1 H, 5a-H), 3.70Ϫ3.87
Chem. Int. Ed. Engl. 1986, 25, 212Ϫ235.
R. R. Schmidt, W. Kinzy, Adv. Carbohydr. Chem. Biochem.
3
2
(m, 8 H), 3.97 (t, J ϭ 9.1 Hz, 1 H, 4a-H), 4.15 (d, J ϭ 12.9 Hz,
1 H, 1/2 CH2Ph), 4.17Ϫ4.26 (m, 5 H), 4.38 (d, J1,2 ϭ 8.0 Hz, 1 H,
1d-H), 4.47 (d, 2J ϭ 12.1 Hz, 1 H, 1/2 CH2Ph), 4.51Ϫ4.65 (m, 5
H, 1a-H, 2 CH2Ph), 4.68 (d, J1,2 ϭ 8.0 Hz, 1 H, 1b-H), 4.71-4-75
(dd, 2J ϭ 11.8 Hz, 2 H, CH2Ph), 4.80 (dd, 1 H, 3b-H), 4.88 (d,
2J ϭ 12.0 Hz, 1 H, 1/2 CH2Ph), 5.0Ϫ5.1 (m, 5 H, 2d-H, 2 CH2Ph),
[5]
1994, 50, 21Ϫ123.
[6]
S. J. Danishefsky, M. T. Bilodeau, Angew. Chem. 1996, 108,
1483Ϫ1522; Angew. Chem. Int. Ed. Engl. 1996, 35, 1380Ϫ1419.
[7]
P. J. Garegg, Adv. Carbohydr. Chem. Biochem. 1996, 52,
179Ϫ205.
Eur. J. Org. Chem. 2004, 2826Ϫ2832
2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2831